FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066623930> ?p ?o ?g. }

• W2066623930 abstract "To the authors' knowledge, no previous studies have been reported with the combination of paclitaxel and oral cyclophosphamide in patients with metastatic bladder cancer. A phase 1/2 study was conducted of paclitaxel in combination with oral cyclophosphamide for patients with advanced urothelial bladder cancer who had been previously treated with gemcitabine/cisplatin chemotherapy as first-line metastatic treatment.This was a single-arm phase 1/2 study. Patients were treated with paclitaxel and oral cyclophosphamide at 3-week intervals until disease progression or irreversible toxicity occurred. Primary endpoints were to determine the maximum tolerated doses (MTD) and objective response rate; secondary endpoints were safety, time to disease progression (TTP), and overall survival (OS).Forty-four patients were enrolled. Dose levels of paclitaxel of 175 mg/m(2) (Day 1) and cyclophosphamide of 50 mg (Days 1-7 orally) (dose level I) of a 21-day cycle were tolerated without dose-limiting toxicities (DLTs). At a cyclophosphamide dose of 100 mg (dose level II) the MTD was exceeded; 3 of 6 patients experienced a DLT (grade 3 constipation and grade 4 neutropenia and thrombocytopenia [toxicities were graded using National Cancer Institute Common Toxicity Criteria (version 3.0)]). Dose level I was expanded and determined to be the MTD. A total of 32 patients were treated at dose level I in the phase 2 portion. Partial responses were observed in 31% of patients (10 of 32 patients; 95% confidence interval [95% CI], 17%-45%). Grade 1/2 vomiting, peripheral neuropathy, and neutropenia were the most common side effects, noted in 11 (34%), 8 (25%), and 10 (31%) patients, respectively. The median TTP was 5 months (95% CI, 2 months-7.5 months) and the median OS was 8 months (95% CI, 4 months-14 months).The combination of paclitaxel and cyclophosphamide is well tolerated and associated with promising efficacy. Further trials are needed to confirm these preliminary results." @default.
• W2066623930 created "2016-06-24" @default.
• W2066623930 creator A5008674075 @default.
• W2066623930 creator A5024021311 @default.
• W2066623930 creator A5027006820 @default.
• W2066623930 creator A5032217427 @default.
• W2066623930 creator A5047335434 @default.
• W2066623930 creator A5050834286 @default.
• W2066623930 creator A5051536719 @default.
• W2066623930 creator A5064453022 @default.
• W2066623930 creator A5078562748 @default.
• W2066623930 creator A5080243444 @default.
• W2066623930 date "2009-02-01" @default.
• W2066623930 modified "2023-09-26" @default.
• W2066623930 title "Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients" @default.
• W2066623930 cites W1939723756 @default.
• W2066623930 cites W1974195645 @default.
• W2066623930 cites W1980377320 @default.
• W2066623930 cites W2001284779 @default.
• W2066623930 cites W2018929154 @default.
• W2066623930 cites W2023741846 @default.
• W2066623930 cites W2047050537 @default.
• W2066623930 cites W2054341710 @default.
• W2066623930 cites W2066984265 @default.
• W2066623930 cites W2069549911 @default.
• W2066623930 cites W2080969265 @default.
• W2066623930 cites W2083728490 @default.
• W2066623930 cites W2090906593 @default.
• W2066623930 cites W2102392974 @default.
• W2066623930 cites W2103257412 @default.
• W2066623930 cites W2114859751 @default.
• W2066623930 cites W2133330931 @default.
• W2066623930 cites W2139248078 @default.
• W2066623930 cites W2151747207 @default.
• W2066623930 cites W2161714684 @default.
• W2066623930 cites W2163940216 @default.
• W2066623930 cites W2246945802 @default.
• W2066623930 cites W4246715702 @default.
• W2066623930 cites W4323966482 @default.
• W2066623930 doi "https://doi.org/10.1002/cncr.24055" @default.
• W2066623930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19117344" @default.
• W2066623930 hasPublicationYear "2009" @default.
• W2066623930 type Work @default.
• W2066623930 sameAs 2066623930 @default.
• W2066623930 citedByCount "18" @default.
• W2066623930 countsByYear W20666239302012 @default.
• W2066623930 countsByYear W20666239302013 @default.
• W2066623930 countsByYear W20666239302014 @default.
• W2066623930 countsByYear W20666239302015 @default.
• W2066623930 countsByYear W20666239302016 @default.
• W2066623930 countsByYear W20666239302021 @default.
• W2066623930 crossrefType "journal-article" @default.
• W2066623930 hasAuthorship W2066623930A5008674075 @default.
• W2066623930 hasAuthorship W2066623930A5024021311 @default.
• W2066623930 hasAuthorship W2066623930A5027006820 @default.
• W2066623930 hasAuthorship W2066623930A5032217427 @default.
• W2066623930 hasAuthorship W2066623930A5047335434 @default.
• W2066623930 hasAuthorship W2066623930A5050834286 @default.
• W2066623930 hasAuthorship W2066623930A5051536719 @default.
• W2066623930 hasAuthorship W2066623930A5064453022 @default.
• W2066623930 hasAuthorship W2066623930A5078562748 @default.
• W2066623930 hasAuthorship W2066623930A5080243444 @default.
• W2066623930 hasConcept C121608353 @default.
• W2066623930 hasConcept C126322002 @default.
• W2066623930 hasConcept C126894567 @default.
• W2066623930 hasConcept C141071460 @default.
• W2066623930 hasConcept C143998085 @default.
• W2066623930 hasConcept C2775930923 @default.
• W2066623930 hasConcept C2776694085 @default.
• W2066623930 hasConcept C2776755627 @default.
• W2066623930 hasConcept C2777063308 @default.
• W2066623930 hasConcept C2777292972 @default.
• W2066623930 hasConcept C2778850193 @default.
• W2066623930 hasConcept C2780258809 @default.
• W2066623930 hasConcept C2780352672 @default.
• W2066623930 hasConcept C29730261 @default.
• W2066623930 hasConcept C530470458 @default.
• W2066623930 hasConcept C71924100 @default.
• W2066623930 hasConcept C90924648 @default.
• W2066623930 hasConceptScore W2066623930C121608353 @default.
• W2066623930 hasConceptScore W2066623930C126322002 @default.
• W2066623930 hasConceptScore W2066623930C126894567 @default.
• W2066623930 hasConceptScore W2066623930C141071460 @default.
• W2066623930 hasConceptScore W2066623930C143998085 @default.
• W2066623930 hasConceptScore W2066623930C2775930923 @default.
• W2066623930 hasConceptScore W2066623930C2776694085 @default.
• W2066623930 hasConceptScore W2066623930C2776755627 @default.
• W2066623930 hasConceptScore W2066623930C2777063308 @default.
• W2066623930 hasConceptScore W2066623930C2777292972 @default.
• W2066623930 hasConceptScore W2066623930C2778850193 @default.
• W2066623930 hasConceptScore W2066623930C2780258809 @default.
• W2066623930 hasConceptScore W2066623930C2780352672 @default.
• W2066623930 hasConceptScore W2066623930C29730261 @default.
• W2066623930 hasConceptScore W2066623930C530470458 @default.
• W2066623930 hasConceptScore W2066623930C71924100 @default.
• W2066623930 hasConceptScore W2066623930C90924648 @default.
• W2066623930 hasLocation W20666239301 @default.
• W2066623930 hasLocation W20666239302 @default.
• W2066623930 hasOpenAccess W2066623930 @default.
• W2066623930 hasPrimaryLocation W20666239301 @default.

• next